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Peter R. Durie,6,7 Andrew D. Paterson,2,8 Johanna M. Rommens,2,9 Lisa J. Strug,1,2,* and Lei Sun1,10,*
Gene-based, pathway, and other multivariate association methods are motivated by the possibility of GxG and GxE interactions; how-
ever, accounting for such interactions is limited by the challenges associated with adequate modeling information. Here we propose an
easy-to-implement joint location-scale (JLS) association testing framework for single-variant and multivariate analysis that accounts for
interactions without explicitly modeling them.We apply the JLS method to a gene-set analysis of cystic fibrosis (CF) lung disease, which
is influenced by multiple environmental and genetic factors. We identify and replicate an association between the constituents of
the apical plasma membrane and CF lung disease (p ¼ 0.0099 and p ¼ 0.0180, respectively) and highlight a role for the SLC9A3-
SLC9A3R1/2-EZR complex in contributing to CF lung disease. Many association studies could benefit from re-analysis with the JLS
method that leverages complex genetic architecture for SNP, gene, and pathway identification. Analytical verification, simulation,
and additional proof-of-principle applications support our approach.Introduction
Identifying the genetic architecture of complex traits re-
quires analytic strategies that move beyond single-variant
association tests. Multivariate analyses such as gene-based,
gene-by-gene interaction (GxG), gene-by-environment
interaction (GxE), gene-set, and pathway analyses are
now commonly implemented,1–5 yet, one rarely sees
GxG or GxE explicitly accounted for within gene-set and
pathway analyses.6 The specification of interacting vari-
ables that probably differ between genes in gene sets and
pathways is not straightforward. Interacting exposure vari-
ables (termed E hereafter) could include contributing envi-
ronmental factors or SNPs or haplotypes from the same
region or at other susceptibility loci. Missing or incorrect
information on interacting factors, as well as associated
computational burden, might also limit more comprehen-
sive surveys of the whole genome for disease association.
Here we provide an easy-to-implement, straightforward
solution to exploit potential GxG and GxE in gene-set
and pathway analyses, and we illustrate the power of
such an approach in a gene-modifier study of lung disease
in cystic fibrosis (CF [MIM: 219700]).
CF is a life-limiting genetic disease, with the majority of
mortality due to lung disease. CF is caused by mutations
in the cystic fibrosis transmembrane conductance regu-
lator (CFTR [MIM: 602421]). Individuals with the same
loss-of-function CFTR mutations have variable disease
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The Aorgans, suggesting that variation in other (modifier) genes
might play a role in disease pathophysiology.7 A major
source of pathophysiology in CF is impaired fluid and
electrolyte flux in CF-affected organ epithelia. Sun et al.5
hypothesized that regulators of fluid, solute, and ion
transport that physically co-localize with CFTR would
play a role in determining CF disease severity. Using a
composite tissue gene set that corresponds to 157 gene
products localized to the apical plasma membrane of
epithelia, a multivariate sum-test provided evidence that
many of the constituent gene products contribute to
early intestinal obstruction (called meconium ileus
[MIM: 614665]) in CF. Meconium ileus is heritable
(~88% estimated heritability) and presents at birth in
~15% of CF-affected individuals,8 with limited opportu-
nity for environmental involvement.
Lung disease in CF is distinct, being progressive and
notably affected by environmental exposures such as
infection history, secondhand smoke, air pollution, and
ambient air temperature,9–11 with a ~50% estimated herita-
bility.12 Similar to the intestinal epithelia, the apical mem-
brane constituents of lung epithelia should likewise
contribute to disease. Testing this, or any hypothesis in
CF lung disease, however, has the added difficulty of being
able to specify and collect accurate information on the
contributing exposure variables and model the potential
GxE. Therefore, an alternative association testing method-
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For a biallelic SNP, a genetic interaction (either GxG or
GxE) on a quantitative phenotype will lead to differences
in phenotypic distribution across the three genotypes,
leading to differences in phenotypic variance (scale).13 In
light of this, Levene’s scale test of equality of variance14
has been proposed as a method of prioritizing SNPs for
subsequent GxG and GxE studies,13,15 in contrast to the
standard mean (location) test (i.e., testing for phenotypic
differences in mean across genotypes). The advantage of
using variance testing to incorporate GxG or GxE is that
exposures need not be specified, and the enormous
multiple testing burden of formally examining all possible
pair-wise interactions is removed. Variance-only testing,
however, has limited power to detect SNPs displaying
main effects only.
Focusing on single-SNP analysis, Aschard et al.16 pro-
posed a test that compares the percentiles of phenotypic
values between genotypes, capturing mean, variance, and
other differences. Although this approach comprehen-
sively evaluates the phenotypic distribution between
genotypes, it sacrifices statistical power when a (approxi-
mately) normally distributed trait is sufficiently summa-
rized by its mean and variance. Furthermore, the distribu-
tion test statistic requires computationally intensive
permutation-based methods for p value estimation that
are challenging to implement on a genome-wide scale.
Cao et al.17 considered a joint test of mean and variance
differences by using a full likelihood approach based on
linear regression models. The likelihood ratio test (LRT)
statistic follows an asymptotic chi-square distribution un-
der the null hypothesis. The LRT approach can increase
power but is more sensitive to model assumptions such
as normality. Therefore, Cao et al.17 proposed a parametric
bootstrapmethod to calculate ‘‘honest’’ p values at the cost
of computational efficiency. For both the LRT and distribu-
tion methods, implementation difficulties arise for multi-
variate (e.g., gene-based, gene-set, and pathway) analyses
(see Appendix A).
Here we propose an easy-to-implement joint location-
scale (JLS) testing framework that simultaneously tests
the null hypothesis of equal mean and equal variance be-
tween genotypes, by aggregating association evidence
from the individual location-only and scale-only tests,
focusing on Fisher’s method of combining information
(JLS-Fisher). The proposed method detects association in
the presence of underlying genetic main and/or interac-
tion effects, without specifying the interactors; it allows
any type of individual location and scale tests to be com-
bined, making it particularly useful for gene-based, gene-
set, and pathway analyses.
Using two proof-of-principle examples in the single-
variant testing setting, where GxE interactions have been
shown to exist from previous studies, we demonstrate
the power of the JLS method. The first example pertains
to a locus that determines glycosylated hemoglobin
(HbA1c) levels based on a genome-wide association study
(GWAS) of type 1 diabetes (T1D [MIM: 222100]) complica-126 The American Journal of Human Genetics 97, 125–138, July 2, 20tions.18 The second pertains to determinants of CF lung
disease severity.19 For these examples, the known environ-
mental interactors are not explicitly modeled, but we
leverage their existence to identify genetic contributors
to HbA1c and CF lung disease.
We then use the multivariate JLS method to identify
and replicate an association between the apical gene set,
and the SLC9A3 complex within the set, and lung disease
severity in CF; this finding would have been missed by
the traditional multivariate gene-set tests that do not
account for (heterogeneous) GxG and GxE interactions.
Through extensive simulation analyses, we demonstrate
that the proposed JLS method has good type 1 error
control with improved power compared to other testing
options, and, in contrast to the recently proposed distri-
bution16 and LRT joint testing methods,17 can be easily
implemented in the context of gene-set and pathway
analyses.Material and Methods
Genetic Model and Notation
Let Y be a quantitative trait andG be the minor allele count for the
SNP under investigation (G¼ 0, 1, or 2); the additive assumption is
not critical to the method development. Let E be an exposure var-
iable interacting with the genetic factor. This exposure E could
reflect continuous or categorical measures of environmental or ge-
netic background. The underlying true genetic model can include
main effects of both G (bG) and E (bE) on Y, as well as the interac-
tion effect (bGE):
Y  b0 þ bGGþ bEEþ bGEGEþ ε: (Equation 1)
We assume that the trait Y is normally distributed with unit vari-
ance conditional upon G and E, in other words, Var(Y jG ¼ g,
E ¼ e) ¼ 1 and ε  N ð0; 1Þ.
When considering only G, the working model would reduce to
Y  b0 þ bGGþ εG: (Equation 2)
Pare et al.13 showed that the conditional variance of Y conditional
on G alone could be expressed as s2G ¼ Var(YjG ¼ g) ¼
ðbE þ bGEgÞ 2 þ 1. Thus, if an interaction effect was present (i.e.,
bGEs0), the trait variance would differ between genotypes.
Joint Location-Scale Testing Procedure for Single-SNP
Analysis
Our proposed JLS testing framework, based on the working model
of Equation 2, tests the following null hypothesis:
Hjoint0 : bG ¼ 0 and si ¼ sj for all isj; i; j ¼ 0; 1; 2:
The alternative hypothesis of interest is
Hjoint1 : bGs0 or sissj for some isj:
For a SNP under study, different JLS test statistics can be consid-
ered. Let pL be the p value for the location test of choice (i.e.,
testingHlocation0 : bG ¼ 0 using, for example, ordinary least-squares
regression), and pS be the p value for the scale test of choice
(i.e., testing Hscale0 : si ¼ sj for all isj using, for example, Levene’s
test). We first consider Fisher’s method (JLS-Fisher) to combine15
the association evidence from the individual location and scale
tests. The JLS-Fisher statistic is defined as
WF ¼ 2

logðpLÞ þ log

pS

:
Large values ofWF correspond to small values of pL and/or pS and
provide evidence against the null H
joint
0 . If pL and pS are indepen-
dent under H
joint
0 , WF is distributed as a c
2
4 random variable.
Although Fisher’s method here is used to combine evidence
from two tests applied to the same sample, the assumption of
independence between pL and pS under H
joint
0 holds theoretically
for a normally distributed trait (Appendix A, Lemma 1), as well
as empirically for approximately normally distributed traits in
finite samples (Figures S1 and S2, Tables S1 and S2).
One can also consider the minimum p value (JLS-minP)
approach, or various alternatives based on combining the individ-
ual test statistics themselves with or without weights.20–23 The JLS-
minP statistic is defined as
WM ¼ min

pL; pS

:
If pL and pS are independent under H
joint
0 , WM is distributed as a
Beta random variable (with shape parameters 1 and 2) where small
values of WM correspond to small values of pL and/or pS and evi-
dence against the null.
Joint Location-Scale Testing Procedure for Gene-Set
Analysis
The chosen JLS test statistic (e.g., WF) for single-SNP analysis can
then be used for implementing gene-based, gene-set, or pathway
analysis in a direct fashion.
Assume that J SNPs have been annotated to a gene or gene-set of
interest. For each SNP j, the JLS-Fisher test statistic (e.g.,WF,j) is first
obtained and then the association evidence can be aggregated
across the SNPs by considering, for example, the sum statistic,5P
jWF;j. To account for LD between SNPs, the overall association
evidence can be evaluated by a phenotype-permutation approach
where the empirical p value is the proportion of K permutation
replicates with sum statistics more extreme than the observed
value. Because this multivariate method analyzes all J SNPs simul-
taneously, the number of permutations need not be exceedingly
large and K ¼ 10,000 provides accurate estimates for p values in
the range of 0.05. If multiple genes or gene-sets are of interest,
more replicates would be required to adjust for the corresponding
number of hypothesis tests.
To compare strength of association evidence between sets of var-
iants within the same gene or across different genes, an extension
of the gene-set approach can be implemented. Sum statistics are
obtained as previously described for each group of variants, then
calibrated by the respective number of variants. The difference be-
tween the two proportional sum statistics is the test statistic of
interest,
DF ¼ 1
J
X
j
WF;j  1
K
X
k
WF;k;
where the j ¼ 1,.,J and k ¼ 1,.,K subscripts index the competing
sets of variants, and the F subscript indicates that the variant-spe-
cific joint location-scale statistics are obtained by Fisher’s method
(although other methods of combining such as minP could be
used as well). The significance of DF can be evaluated with the
phenotype-permutation approach as described above.
In all applications, genotypes were coded additively (G ¼ 0, 1
or 2), and for X chromosome SNPs, female and male genotypesThe Awere analyzed together and coded as G ¼ 0, 1, or 2 and G ¼ 0
or 2, respectively.
Application Data: HbA1c Levels in Type 1 Diabetes
and Cystic Fibrosis Lung Disease
We tested the proposed JLS approach with applications to genetic
association studies of HbA1c levels in type 1 diabetes and lung dis-
ease in cystic fibrosis.
The T1D application used the Diabetes Control and Complica-
tions Trial (DCCT) sample in which 667 individuals were conven-
tionally treated and 637 intensively treated.18 In this sample, an
earlier GWAS of HbA1c levels in type 1 diabetes18 showed that
rs1358030 near SORCS1 (10q25.1 [MIM: 606283]) interacts with
treatment type (conventional versus intensive) on HbA1c levels
(quarterly measured values spanning 6.5 years). To demonstrate
that the JLS testing framework could leverage the interaction effect
withoutknowledge of the interactingvariable,we analyzed the asso-
ciation of rs1358030 with the average, inverse normal transformed
HbA1c value, assuming the treatment variable was not available.
The CF application involves association studies of an averaged
lung function measure, forced expiratory volume in 1 s, adjusted
for sex, age, height, and mortality, and normalized (SaKnorm),24
using data from the Canadian Cystic Fibrosis Gene Modifier Study
(CGS).25 To reduce the duration of heterogeneous environmental
exposures that were not measured, and recognizing that age can
serve as a surrogate for these exposures, we19 previously restricted
our (location-only) analysis to lung function measures from pedi-
atric ages (<18 years, n ¼ 815 subjects from 753 unique families),
analyzing eight SNPs in three genes, SLC9A3 (MIM: 182307),
SLC6A14 (MIM: 300444), and SLC26A9 (MIM: 608481), previ-
ously identified as associated with meconium ileus in a hypothe-
sis-driven GWAS (GWAS-HD).5 This approach involved a 46%
reduction in sample size, and that the age restriction be fixed for
all variants, despite the possibility that the optimal exposure
(here, age) is gene specific. Here we re-analyzed the SNPs
with the individual location-only and scale-only tests, as well as
the joint JLS-Fisher, JLS-minP, LRT,17 and distribution16 tests,
removing the age restriction and using the full CGS sample
(n ¼ 1,409 unrelated subjects). For comparison, the location-
only analyses restricted to the pediatric population using different
age cut-off points were also investigated.
With the full CGS sample, we further tested the hypothesis that
multiple proteins present on the apical plasma membrane
contribute to lung disease severity as measured by SakNorm; the
hypothesis was considered previously for meconium ileus suscep-
tibility in CF.5 In total, 3,814 GWAS SNPs (MAF> 0.02) were anno-
tated to within 510 kb of 155 apical genes obtained from the
Gene Ontology project.5 The JLS-Fisher test was first applied to
each SNP, and the SNP-specific test statistic was then aggregated
across all SNPs to perform themultivariate apical gene-set analysis.
We then used an independent French sample (n ¼ 1,232) for repli-
cation. Imputation based on 1000 Genomes26,27 (as outlined in
the Online Methods of Sun et al.5) was used to assess regional as-
sociation within the SLC9A3R1, SLC9A3R2, and EZR binding sites
of SLC9A3.
Institutional review committees at all participating institutions
for the DCCT T1D study as well as all Canadian CF clinics
approved this study. Consent was also obtained for participants
from France with procedural approval (CPP 2004/15) and informa-
tion collection approval by CNIL (04.404). Data collection, geno-
typing, and quality-control procedures are reported elsewhere for
the T1D18 and CF (Canadian and French) studies.5,25merican Journal of Human Genetics 97, 125–138, July 2, 2015 127
JLS Method Evaluation by Simulation
We conducted extensive simulation analyses to evaluate the per-
formance of the proposed JLS-Fisher and JLS-minP tests for sin-
gle-variant analysis and compared them with the individual
location-only and scale-only tests, as well as the distribution
test16 and the LRT.17 We also conducted a sensitivity analysis on
the various tests, studying the impact of poorly captured geno-
types that can be expected from imputed datasets. Simulation de-
tails are provided in Appendix A.Results
Type 1 Diabetes Complications
Traditional analysis using the individual location-only
test did not yield a genome-wide significant association
of p < 5 3 108 (as previously proposed by Dudbridge
and Gusnanto28) between rs1358030 and HbA1c (p ¼
2.3 3 107), whereas the JLS-Fisher method did (p ¼
4.9 3 108). Genome-wide significance was also not
achieved by the scale-only test (p ¼ 0.01), the distribution
test (p ¼ 1.7 3 107, estimated from 108 permutation
replicates), the LRT (p ¼ 2.0 3 107), or the JLS-minP test
(p ¼ 4.6 3 107).
Knowing the treatment information, Paterson et al.18
was able to explicitly model this interactor and identified
rs1358030 as genome-wide significantly associated with
HbA1c levels and interacting with treatment type (p ¼
3.8 3 1010 and p ¼ 0.013 for the main and interaction
effect, respectively).
Cystic Fibrosis Lung Disease: Single-Variant
Association Analysis
We first noted in Table 1 that all methods (the joint and
individual tests using the full sample or various sub-
samples) consistently highlighted that variants in both
SLC9A3 and SLC6A14 are associated with the lung pheno-
type, but not those in SLC26A9. For the individual loca-
tion-only test, although the age cut-off of <18 years
appears to be ideal for rs17563161 in SLC9A3 resulting
in the smallest p value (p ¼ 3.3 3 105) even with
the smaller sample size (n ¼ 753), a different cut-off
(<20 years, n ¼ 830) yields the most significant loca-
tion-only test result for rs3788766 in SLC6A14 (p ¼
0.0002). This illustrates the challenge of specifying and
modeling interacting exposures in the context of multiple
SNPs and genes of interest.
With the entire sample of CF-affected individuals
(n ¼ 1,409) encompassing a wider age range and thus
greater variability of environmental exposures, we indeed
observed evidence for scale differences in the lung pheno-
type (Levene’s test p ¼ 0.01–0.08) for variants in SLC9A3
and SLC6A14, revealing the possibility of GxG or GxE
interaction. (Table S3 provides evidence for SNP-by-age
interaction effects from regression models directly incor-
porating age.) Compared with the distribution and LRT
joint tests, the JLS-Fisher test consistently provides the
smallest p values for variants in SLC9A3 and SLC6A14.128 The American Journal of Human Genetics 97, 125–138, July 2, 20Cystic Fibrosis Lung Disease: Gene-Set Association
Analysis
We observed evidence of an association between the apical
gene set and SakNorm (JLS-Fisher permutation p ¼ 0.0099;
Figures 1A and 1B and Table 2). Comparison with the indi-
vidual location-only and scale-only tests showed that this
association does not reach statistical significance using
the conventional gene-set location test (regression permu-
tation p¼ 0.0876; Figures 1C and 1D) whereas the variance
component contributed a significant result (Levene’s per-
mutation p ¼ 0.0222; Figures 1E and 1F).
Examination of the SNP- and gene-specific JLS-Fisher
p values and rankings showed SLC9A3 to be the top ranked
(Table S4), with three of the top four ranked SNPs being
annotated to SLC9A3. This provided consistent support
for the relationship between SLC9A3 and lung function
as previously reported (Table 1).19,29 In the independent
French sample (n ¼ 1,232), we observed replication of
the apical hypothesis via the JLS-Fisher test (permutation
p ¼ 0.0180; Figures 2A and 2B and Table 2). Again, the
standard location testing approach, by itself, was not
powerful enough to detect the association (regression per-
mutation p ¼ 0.2058; Figures 2C and 2D), and the added
contribution from the scale-testing component was bene-
ficial (Levene’s permutation p ¼ 0.0077; Figures 2E and
2F). After excluding all ten genotyped SNPs annotated to
SLC9A3, the apical gene-set test in both the CGS and
French samples remained significant (Table 2), suggesting
that the JLS-Fisher method identified multiple additional
associations within the gene set, beyond the known
SLC9A3 contribution.
Three of the five top-ranked genes in the apical gene set
were SLC9A3, SLC9A3R2 (MIM: 606553), and EZR (MIM:
123900), with ten genes in total displaying JLS-Fisher p <
0.05 (Table S4). Of these top five, protein product interac-
tions are known between (1) SLC9A3 (also known as
NHE3) and SLC9A3R2 (‘‘SLC9A3 regulator 2,’’ also known
as E3KARP or NHERF2), (2) SLC9A3 and EZR, and (3)
SLC9A3R2 and EZR. SLC9A3R1, or ‘‘SLC9A3 regulator 1’’
(also known as EBP50 or NHERF1), is recognized as a
paralog of SLC9A3R2 with comparable binding sites to
both SLC9A3 and EZR (reviewed in Donowitz and Li30);
SLC9A3R1 (MIM: 604990) was the 21st ranked. Based on
interaction investigations typically involving intestinal
and kidney tissues, a current paradigm is that EZR provides
anchorages for the SLC9A3 regulators to the actin cytoskel-
eton, and probably also facilitates early trafficking of
SLC9A3 from the Golgi to the cell periphery, with eventual
‘‘hand-off’’ to the SLC9A3 regulators. The SLC9A3 regula-
tors help to maintain SLC9A3 at the apical membrane
and facilitate its dynamic shuffling with endosomes and
internal vesicles.30
Notably, variants within the SLC9A3 complex compo-
nent genes are significantly associated as a set in the CGS
sample using the JLS-Fisher or regression tests (p <
0.0001 and p < 0.0001, respectively; Table 2). The French
sample provided replicated support for the SLC9A315
Table 1. Candidate-Gene Study of Cystic Fibrosis Lung Disease Severity as Measured by SaKnorm in the Canadian Gene Modifier Study Sample
Chr Gene SNP BPa MAFb
Full CGS Sample (n ¼ 1,409) CGS Pediatric Subsample
Location/
Regression
Scale/
Levene
Joint Tests
Location/Regression
<16 years <18 yearsd <20 years
JLS-Fisher JLS-minP LRT Distributionc (n ¼ 653) (n ¼ 753) (n ¼ 830)
1 SLC26A9 rs7512462 204,166,218 0.41 0.30 0.58 0.48 0.52 0.64 0.84 0.41 0.58 0.79
1 SLC26A9 rs4077468 204,181,380 0.42 0.53 0.61 0.69 0.78 0.65 0.75 0.14 0.20 0.32
1 SLC26A9 rs12047830 204,183,322 0.49 0.55 0.15 0.29 0.28 0.38 0.43 0.09 0.12 0.21
1 SLC26A9 rs7419153 204,183,932 0.37 0.50 0.06 0.14 0.12 0.18 0.42 0.25 0.33 0.51
5e SLC9A3 rs17563161 550,624 0.26 0.0004 0.02 0.0001 0.0008 0.0008 0.002 0.0001 3.3 3 105 8.0 3 105
X SLC6A14 rs12839137 115,479,578 0.24 0.02 0.08 0.01 0.05 0.03 0.04 0.02 0.04 0.02
Xe SLC6A14 rs5905283 115,479,909 0.49 0.009 0.07 0.005 0.02 0.02 0.03 0.02 0.01 0.01
Xe SLC6A14 rs3788766 115,480,867 0.40 0.001 0.01 0.0002 0.002 0.0005 0.002 0.0004 0.0005 0.0002
SaKnorm24 (normalized, averaged sex-, age-, height-, mortality-adjusted forced expiratory volume in 1 s; FEV1) was used as the lung function measure. Analysis was performed on eight SNPs in three candidate genes
previously identified as associated with meconium ileus5 and subsequently studied for association with SaKnorm in a pediatric subsample.19 Individual location-only and scale-only tests, joint location-scale Fisher (JLS-Fisher),
joint location-scale minimum-P (JLS-minP), the likelihood ratio test (LRT) of Cao et al.,17 and the distribution test of Aschard et al.16 were performed in the full sample of 1,409 unrelated individuals. For comparison, the
location-only test was performed in three CGS pediatric subsamples using different age cutoffs of 16, 18, and 20 years.
ahg18 assembly (March 2006; NCBI36).
bMAF is similar across the pediatric subsets (see Table S8).
cDistribution test p values were estimated from 105 permutation replicates.
dPediatric subset cutoff (<18 years) used in Li et al.;19 subset here includes only unrelated subjects (n ¼ 753).
eSignificant variants (p < 0.05 corrected for multiple testing) reported in Li et al.19
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Figure 1. Apical Gene-Set Association
Analysis of CF Lung Disease Severity as
Measured by SaKnorm in the Canadian
Gene Modifier Study Discovery Sample
of 1,409 Subjects
SaKnorm24 (sex-, age-, and mortality-
adjusted, normalized forced expiratory
volume in 1 s; FEV1) was used as the
lung function measure. In total, 3,814
GWAS SNPs (MAF > 0.02) were annotated
to within 510 kb of the 155 apical genes
obtained from the Gene Ontology data-
base.5
(A, C, E) Quantile-quantile plots (QQ-
plots) of the SNP-specific association test
statistics of the apical SNPs via (A) the pro-
posed joint location-scale test (JLS-Fisher),
(C) the regression based location-only test,
and (E) Levene’s scale-only test. QQ-plots
of the observed association statistics are
shown in red, and the QQ-plots of the sta-
tistics calculated from the 10,000 pheno-
type-permutated replicates are shown in
gray.
(B, D, F) Corresponding gene-set associa-
tion analysis results for (B) the JLS-Fisher
test (permutation p ¼ 0.0099), (D) the
standard regression-based location-only
test (permutation p¼ 0.0876), and (F) Lev-
ene’s scale-only test (permutation p ¼
0.0222). For each figure, the observed
sum statistic aggregated across all 3,814
SNPs, as described in the Material and
Methods, is shown as a vertical line in
red, and the sum statistics calculated
from the 10,000 phenotype-permutated
replicates is shown as a histogram.complex using the JLS-Fisher test (p¼ 0.0415), although in
this latter sample, SLC9A3R1 is more highly ranked than
SLC9A3R2 and EZR. Removal of the four-gene set,
SLC9A3, SLC9A3R1/2, and EZR, and the re-testing of the
apical gene set with the remaining 151 genes suggests
that association(s) beyond the SLC9A3 regulator com-
plexes also exist (JLS-Fisher p ¼ 0.0329 and 0.0201 in the
CGS and French samples, respectively).
SLC9A3 contains multi-membrane spanning motifs in
its amino portion to facilitate transport function, with a
large cytosolic carboxyl portion that affords regulation130 The American Journal of Human Genetics 97, 125–138, July 2, 2015with binding sites for multiple inter-
actors. Although there is significant
LD that extends throughout the
gene (Figure 3), there was evidence
suggesting greater association for
variants as a group from the region
corresponding to the regulatory
portion, compared to the transport-
ing portion (regression, Levene’s,
and JLS-Fisher permutation p ¼
0.0391, 0.312, and 0.1254, respec-
tively). Amino acids 586–660 of
SLC9A3 bind the SLC9A3 regulatorswhere an exonic nucleotide variant (rs2230437) is
associated with lung function (JLS-Fisher p ¼ 7.6 3
106). This synonymous change is in high LD (r2 > 0.8)
with four other variants, all with similar association evi-
dence (rs11743825, rs41282625, 5:475625:GC_G, and
rs11745923 with JLS-Fisher p ¼ 1.4 3 106, 2.2 3 106,
2.3 3 106, and 2.7 3 106, respectively), and all in
noncoding positions. There are also no associated
coding variants in the major EZR binding site from
amino acids 519–595. Similarly, there are no coding
variants in the respective PDZ domains of the SLC9A3
Table 2. Apical Gene-Set and SLC9A3 Complex Association
Analysis with CF Lung Disease Severity as Measured by SaKnorm in
the Canadian Gene Modifier Study Discovery Sample and in the
French Replication Sample
Location-
only Test
Scale-only
Test
JLS-Fisher
Test
Apical Gene-Set (3,814 SNPs)
Canadian Discovery Sample 0.0876 0.0222 0.0099
French replication sample 0.2058 0.0077 0.0180
SLC9A3 Gene-Based (10 SNPs)
Canadian Discovery Sample <0.0001 0.0238 0.0001
French replication sample 0.0953 0.0415 0.0286
Apical Gene-Set Excluding SLC9A3 (3,804 SNPs)
Canadian Discovery Sample 0.1319 0.0248 0.0161
French replication sample 0.2139 0.0076 0.0182
SLC9A3 Complex: SLC9A3, SLC9A3R1, SLC9A3R2, and EZR
(38 SNPs)
Canadian Discovery Sample <0.0001 0.0016 <0.0001
French replication sample 0.2390 0.0245 0.0415
Apical Gene-Set Excluding the SLC9A3 Complex (3,776 SNPs)
Canadian Discovery Sample 0.178 0.0329 0.0329
French replication sample 0.2173 0.0099 0.0201
Individual location-only and scale-only tests and the joint location-scale Fisher
(JLS-Fisher) test were performed in the full CGS (n ¼ 1,409) and French (n ¼
1,232) samples using unrelated individuals (see Material and Methods and Re-
sults). p values reported were estimated from 10,000 permutation replicates.regulators or in the FERM domain of EZR that bind
SLC9A3. The imputation analysis would have captured
the major variation in this gene. Collectively, because
the constituents or their direct physical interactions
would not appear to be affected, disturbed expression
with altered stoichiometry of components or dynamic
positioning of the SLC9A3 complex might be contrib-
uting to lung disease severity.
Simulation
Results showed that, under the normal model and in
most scenarios considered, the LRTand JLS-Fishermethods
had similar power and were more powerful than the
JLS-minP and distribution tests (Figures 4 and S3) and
the individual location-only and scale-only tests (Figures
S4 and S5).
Investigation of type 1 error (100,000 replicates) under
the normal model showed that all individual and joint
tests considered here maintained the nominal error rates
at the 0.05, 0.005, and 0.0005 levels whenMAF was at least
0.1 and there wereR 20 individuals within each genotype
group (Tables S1 and S2). However, as MAF or the smallest
genotype group size decreased, the LRT method demon-
strated inflated type 1 error (Tables S1 and S2). Departure
from normality also resulted in LRT having inflated type
1 error, as previously discussed in Cao et al.17The ATo study the type 1 error at the genome-wide level, we
conducted association analysis of all 866,995 GWAS SNPs
available in the T1D HbA1c example18 with permuted
phenotype. Results showed that all joint testing methods
provide correct type 1 error control in a finite sample (Fig-
ures S1A, S1D, and S1G, respectively, for the JLS-Fisher, JLS-
minP, and LRTmethods; the distribution test by design has
the correct type 1 error control). However, when stratified
by minor allele frequency (MAF), we observed that,
whereas the JLS-Fisher and JLS-minP tests are slightly
conservative for SNPs with MAF < 0.1 (Figures S1C and
S1F), the LRT method has increased type 1 error rate
(Figure S1I) and would probably not be appropriate when
the size of the genotype group is limited (n < 20). Permu-
tation analysis of all of the 565,884 GWAS SNPs available
in the CF application example5 provided type 1 error
results similar to those of the T1D HbA1c example
(Figure S2).
For the sensitivity analysis, we observed that the individ-
ual location and scale tests and the JLS-Fisher and JLS-minP
tests were not affected by poorly captured genotypes; they
maintained correct type 1 error level irrespective of the
proportion of incorrectly assigned genotypes (Table S5).Discussion
Interactions between genes in gene-set and pathway ana-
lyses are assumed to exist, but they are, in general, not ac-
counted for in current genetic analysis methods. Here we
proposed a joint location-scale (mean-variance) testing
method to account for these relationships as well as
main effects, while avoiding explicit specification of the
contributing interactions. We used this method to identify
the apical membrane constituent gene set as contributing
to CF lung disease and replicated this association in an in-
dependent sample of similarly ascertained CF-affected sub-
jects. Further, we illustrated how the gene-set association
notably benefits from consideration of phenotypic vari-
ance differences that might have been induced by GxG
and/or GxE relationships. This apical gene-set association
was not initially detected via the classical location-only
testing as used in a typical GWAS and provides insight
into interacting genes and exposure variables affecting
lung function.
SNPs in SLC9A3 have been reported to associate with CF
lung disease in two candidate gene studies.19,29 However, a
broader role for the SLC9A3/SLC9A3R2/EZR complex was
not recognized. The JLS-Fisher test ranked these players
as three of the top five contributing apical plasma mem-
brane genes. Variation at SLC9A3R2 or EZR loci and
possibly also SLC9A3R1 given its paralogous function
(and supporting evidence in the French sample) could be
expected to influence CF lung disease severity, presumably
by affecting changes in net SLC9A3 activity. For example,
modest changes in levels of either SLC9A3R2 or EZR could
alter functional apical membrane SLC9A3 levels, just asmerican Journal of Human Genetics 97, 125–138, July 2, 2015 131
Figure 2. Apical Gene-Set Association
Analysis of CF Lung Disease Severity as
Measured by SaKnorm in the French Repli-
cation Sample of 1,232 Subjects
Analysis of the same SNPs as for the Cana-
dian discovery sample (legend of Figure 1).
The replication p values of the gene-set
association analyses are permutation p ¼
0.0180 for the proposed joint location-scale
test (JLS-Fisher) (A and B), permutation p ¼
0.2058 for the standard regression-based
location-only test (C and D), and permuta-
tion p ¼ 0.0077 for Levene’s scale-only test
(E and F). For other details see legend of
Figure 1 and Material and Methods.SLC9A3 locus variants might alter the amount of SLC9A3
transcripts. It should also be noted that the SLC9A3 regula-
tors, with their proximal localization at the apical mem-
brane, could contribute a tethering function for a number
of other apical membrane proteins, including CFTR.31
Given loss of function in CF, SLC9A3 regulators might
not be mediating their effects via CFTR; however, it is
possible that some of the remaining significant apical
membrane components, beyond SLC9A3, utilize the EZR
and/or the SLC9A3 regulator scaffold.32,33
We demonstrated the potential advantage of using the
JLS framework over the conventional location-only or132 The American Journal of Human Genetics 97, 125–138, July 2, 2015scale-only approach in practice. As
proof of principle, we used examples
from an association study of a com-
plex trait (glycemic control in type 1
diabetes) and a modifier study of a
Mendelian disease (lung function in
CF). Both of these datasets provided
examples of a genetic effect on a quan-
titative phenotype that varied based
on another variable (i.e., treatment
regimen and age, respectively). Our re-
sults showed that if the interacting ex-
posure(s) were not known or available,
the JLS method could have improved
power over conventional approaches
in detecting the association.
Recent literature cautions the inves-
tigation and interpretation of signifi-
cant differences in phenotypic vari-
ability across genotypes as well as
observed GxE and GxG interaction
effects.17,34–37 First, variance heteroge-
neity across genotypes can result from
a mean-variance relationship induced
by an inappropriate choice of mea-
surement scale for the phenotype
under investigation. Second, depen-
dence between a causal locus and an
exposure (G or E) can create synthetic
interactions between the exposureand other tagged SNPs in incomplete LD with the causal
locus.36,37 Consequently, we might observe phenotypic
variance heterogeneity across genotypes of a tagged
SNP.17 In these scenarios, however, because there is a true
underlying genotype-phenotype relationship (main effect
of G), it does not matter whether we detect this association
through a location or a scale test, or both; the goal of our
approach is to leverage complex genetic architecture to
efficiently identify the associatedG for follow-up investiga-
tion of causal interactors.
Challenges in understanding and being able to replicate
original findings, particularly in the GxG, GxE, gene-set,
Figure 3. Association and Linkage
Disequilibrium Information across SLC9A3
in the Canadian Gene Modifier Study
Sample
(A) Locus Zoom plot50 displaying the ge-
netic association of 374 imputed SNPs
(see Online Methods of Sun et al.5) within
510 kb of SLC9A3 on chromosome 5.
SNP colors indicate the pairwise correlation
(r2) with the top SNP, rs11743825 at bp
475463. The three vertical lines encompass
the two adjacent binding regions of
SLC9A3R1/SLC9A3R2 (left side of the
dotted line: bp 476,353–476,778) and EZR
(right side of dotted line: bp 476,734–
480,024). Both binding regions are
bounded within the C terminus of the
gene (bp 474,977–482,675).
(B) LD plot indicating pairwise correlation
between imputed SNPs for the CGS sample
using the ‘‘snp.plotter’’ package.51 LD
block colors indicate degree of pairwise
LD (r2). The triangles outlined with black
lines indicate the SLC9A3R1/R2 and EZR
binding regions as described in (A).and pathway analysis setting, is well documented.38 Given
the potential heterogeneity between the Canadian discov-
ery sample and the French replication sample (e.g., clinical
treatment, climate, and air quality), interaction models
could differ between the two samples. Therefore, even if
the exposure variables were precisely measured, a signifi-
cant multivariate interaction effect found in the discovery
sample may not be observed in the replication sample. The
proposed method allows different exposure variables be-
tween genes and between samples, as long as the corre-
sponding underlying phenotype-genotype association
mechanism results in phenotypic mean and/or variance
differences between genotypes of the variants of interest.
A step-by-step guide for application of the JLS framework,
and a discussion of its advantages compared to alternative
approaches, is included as additional considerations in
Appendix A.
In conclusion, we have provided a robust joint location-
scale (JLS) testing framework for the detection of single-
variant, gene-set, or pathway associations involving either
main or interaction effects, or both. This methodology
applies to analysis of a quantitative trait, regardless of
the biological interpretation of the chosen scale of pheno-
typic measurement. Application of the JLS approach iden-The American Journal of Humtified the SLC9A3 regulatory complex
as an important contributor to CF
lung disease, which was completely
missed in previous analyses of the
same data. The JLS association testing
method should be considered for
future gene-set, pathway, and whole-
genome association scans. Further,
JLS should be employed to re-examine
datasets previously analyzed via theconventional location-only or scale-only testing ap-
proaches, for complex traits or complex secondary pheno-
types of Mendelian diseases. The method will help
researchers pinpoint susceptibility loci for additional anal-
ysis toward the understanding of the genetic architecture
of a complex trait.Appendix A
Implementation: Steps for Applying the JLS Testing
Framework
Note that the following implementation is appropriate for
testing association of a phenotype with a genotyped ge-
netic variant (e.g., SNP) or an imputed variant with a
‘‘hard call’’ (i.e., assign individual to the genotype with
the highest posterior imputation probability; high geno-
type uncertainty does not affect type 1 error but will
decrease power), using a sample of unrelated subjects.
1. Check the phenotype of interest for fit to a normal
distribution. If required, adjust the phenotype using
a suitable transformation, e.g., inverse normal trans-
form. If the researcher proceeds using a non-normalan Genetics 97, 125–138, July 2, 2015 133
Figure 4. Power Comparison under Simulation Model 1
Four different testingmethods are examined: the proposed JLS-Fisher (red) and JLS-minP (purple) methods, the distribution test (blue) of
Aschard et al.,16 and the LRT (black) of Cao et al.17 Phenotype values for 2,000 independent subjects were simulated under Model 1,
E[Y] ¼ bGG þ bE1E1 þ bGE1G∙E1, where the MAF of G was 0.3 and the exposure variable E1 was simulated as a Bernoulli variable with
frequency ¼ 0.3. The effect of the exposure E1, bE1, was fixed at 0.3 while the other effects varied.
(A–C) Results when the main genetic effect bG and the interaction effect bGE1 are in the same direction.
(D–F) Results when bG and bGE1 are in opposing direction.
Power was calculated at the 53 108 level based on 500 replicates. For other simulation details, see Appendix A. Additional power results
are in Figures S3–S5.phenotype, only the permutation (resampling-
based) p value analysis will be valid (see step 4b).
2. Choose the individual location and scale tests based
on the distribution of phenotype (normal or non-
normal) or preference (for example, parametric or
non-parametric versions of each test). In the present
paper, our phenotypes were normally distributed
(after transformation) and we chose linear regression
and Levene’s test for the location and scale tests,
respectively.
3. Choose a JLS testing method of combining informa-
tion from the individual location and scale tests and
calculate the JLS test statistic. We acknowledge that
there is no ‘‘most powerful’’ method for all situations
in practice. Based on our experience, we recommend
the use of Fisher’s method (JLS-Fisher) of combining
the association evidence:
WF ¼ 2

logðpLÞ þ log

pS

;
where pL and pS are the individual location and scale test
p values, respectively.
4. Chose the p value estimation method for the JLS
statistic.134 The American Journal of Human Genetics 97, 125–138, July 2, 2015(a) Based on the approximate asymptotic distribu-
tion of the JLS test statistic: For the JLS-Fisher
example, WF is distributed as a c
2
4 random vari-
able, if the chosen individual location and scale
tests are independent of each other under the
null hypothesis. This assumption is correct if
the trait is normally distributed and if the loca-
tion-only test statistic is a function of the com-
plete sufficient statistic (e.g., linear regression
t-statistic, ANOVA F-statistic) and the distribu-
tion of the scale-only test statistic does not
depend on the model parameters (e.g., Levene’s
test or the F-test for equality of variances).
(b) Based on resampling methods such as permuta-
tion:
d Calculate the observed JLS test statistic, e.g.,WF
d Choose the number of permutation replicates,
K, based on the desired p value accuracy.
d Permute the phenotype independently K times
(not valid if subjects are correlated with each
other), and for each replicate k, recalculate the
JLS test statistic, WkF , k ¼ 1,., K.
d Obtain the permutation p value as [the number
of WKF > WF]/K.
Simulation Models
The following three models, as previously considered by
Aschard et al.,16 were used to simulate the data:
Model 1 : E½Y ¼ bGGþ bE1E1 þ bGE1G,E1
Model 2 : E½Y ¼ bE1E1 þ bE2E2 þ bGE1G,E1 þ bGE2G,E2
Model 3 : E½Y ¼ bGE1G,E1
For all three models, the observed genetic variant (G) was
coded additively with minor allele frequency (MAF) of 0.3.
Y was simulated from models with varying effects (bs) and
residual variation (ε) following a standard normal distribu-
tion (mean ¼ 0, standard deviation ¼ 1).
Model 1 is analogous to Equation 1 where Y depended
on the main effects of both G and E1 and an interaction
effect betweenG and E1. The unobserved exposure variable
E1 was binary with frequency 0.3. The main genetic effect
bG took on values of 0.01, 0.05, and 0.1, and the interac-
tion effect bGE1 was varied between 1 and 1 by a grid of
0.1. The main exposure effect bE1 was fixed at 0.3 when
bGE1 was positive and 0.3 when bGE1 was negative.
For Model 2, Y was a function of main effects due to two
unobserved exposures (E1 and E2; both binary with fre-
quency 0.3) and interaction effects between the exposures
and G. bGE1 was always positive and less than 1, whereas
bGE2 was varied between 1 and 1 by a grid of 0.1. bE1
was fixed at 0.3, whereas bE2 was fixed at 0.3 when bGE2
was positive and 0.3 when bGE2 was negative.
For Model 3, Y depended only on the interaction be-
tween G and E1. For this model, the interaction effect
bGE1 and exposure frequency were chosen such that the
observed marginal effect of G was fixed at 10% of the trait
standard deviation.
In all cases, the working associationmodel corresponded
to Equation 2 because information on E1 and E2 was
assumed to be unavailable.
To assess the type 1 error level of the joint location-scale
methods at 0.05, 0.005, and 0.0005 levels, we simulated
100,000 replicate samples of n ¼ 2,000 subjects each
from the null model with no genetic association (i.e.,
bG ¼ 0 and bGE ¼ 0). (Results of n ¼ 1,000 and 4,000 are
qualitatively similar.) To examine the behavior of the
testing methods under small group sizes, we conducted
additional simulations under varied MAF (0.3, 0.2, 0.1,
0.05, and 0.03) as well as under fixed genotype group sizes
where the rare homozygote group size was small (2, 5, 7,
10, 15, or 20) with the other genotype group sizes deter-
mined with respect to Hardy-Weinberg equilibrium. For
comparison, empirical type 1 error rates of the individual
location-only and scale-only tests are also studied, in addi-
tion to the JLS-Fisher and JLS-minP tests, and the LRT of
Cao et al.;17 the distribution test of Aschard et al.16 has
the correct type 1 error by design. Type 1 error control at
the genome-wide level was assessed by phenotype-permu-
tation analysis of the 866,995 T1D GWAS SNPs and
565,884 CF GWAS SNPs.
For the sensitivity analysis of genotype imputation
uncertainty, simulated true genotypes were converted toThe Aprobabilistic genotype data using a Dirichlet distribution
with scale parameters a for the correct genotype category
and (1  a)/2 for the other two;39 a was fixed at values of
1, 0.9, 0.8, 0.7, 0.6, and 0.5. Based on the simulated poste-
rior probabilities, themost-likely genotype for each subject
was the genotype with the highest posterior probability
(i.e., the ‘‘hard call’’); the incorrect call rate under this
Dirichlet model ranges from 0% to 50% on average. The
most-likely genotypes were then used to assess type 1 error
control at the 0.05, 0.005, and 0.0005 levels, using 100,000
simulated replicate samples of n ¼ 2,000, under the
null model of no genetic association (i.e., bG ¼ 0 and
bGE ¼ 0), and MAF ¼ 0.3 for each level of genotype impu-
tation uncertainty (a).
For power evaluation, as in Aschard et al.,16 the results
presented focused on MAF ¼ 0.3 and n ¼ 2,000 for Models
1 and 2 and n ¼ 4,000 for Model 3. Power (at the 5 3 108
level) was estimated from 500 replicates, based on asymp-
totic p values of the tests considered, with the exception of
the distribution test. For the distribution test, p values
required estimation by permutation, and corresponding
power results were from Aschard et al.,16 kindly provided
by Drs. Aschard and Kraft.Lemma 1: Independence of Location-only and Scale-
only Test Statistics under the Null Hypothesis for
Normally Distributed Traits
Let TLocation ¼ bb1=ðS= ﬃﬃﬃﬃﬃﬃSxxp Þ be our location-only test statis-
tic, testing the linear effect of x on Y in a sample of size
n, where S2 ¼ ð1=ðn 2ÞÞPðyi  bb0  bb1xiÞ2, bb0 ¼ y  bb1x,bb1 ¼ Sxy=Sxx, Sxy ¼Pðxi  xÞðyi  yÞ, and Sxx ¼Pðxi  xÞ2
(x ¼ G in Equation 2), and let TScale be our scale-only test
statistic, here defined as Levene’s test statistic for equality
of variances.14
Lemma 1: For the conditional normal model
Yi  N ðb0 þ b1xi; s2xiÞ, where xi ¼ 0,1 or 2, TLocation and
TScale are independent if s
2
0 ¼ s21 ¼ s22.
Proof: For fixed x, Y is normally distributed with con-
stant variance s2 and mean E½Yjx ¼ b0 þ b1x. The density
of Y is

2ps2
n=2
exp

 1
2s2
X
yi  b0  b1xi
2
:
This is an exponential family with three parameters
q ¼ ðq1; q2; q3Þ ¼ ðb1=s2;1=2s2; b0=s2Þ for which the suffi-
cient statistics T ¼ ðT1;T2;T3Þ ¼ ð
P
xiyi;
P
y2i ;
P
yiÞ are
complete. If s20 ¼ s21 ¼ s22, TScale is approximately distrib-
uted as a F31; n3 variable, and it does not depend on q
(i.e., TScale is ancillary for q). Thus, TScale is independent
of T (see page 152 in Lehmann and Romano40). Because
TLocation is a function of T, TLocation and TScale are therefore
independent under the null.
Note that the proof of independence holds regardless of
the version of Levene’s test statistic chosen, provided that
the approximation to the F distribution (or some other
distribution not depending on q) is justifiable. Similarmerican Journal of Human Genetics 97, 125–138, July 2, 2015 135
statements of independence with analogous proofs can be
obtained for other choices of location test statistics such as
the analysis of variance (ANOVA) F-statistic.
Additional Considerations for the JLS Framework
In the most extreme scenario of simulation, i.e., Model 3,
when there were no main G or E effects, the interaction
effect was large (bGE1 ¼ 2), and the unobserved exposure
was rare (prob(E1 ¼ 1) ¼ 0.05), the distribution test was
observed to be more powerful than the JLS-Fisher test
(0.916 versus 0.406) (row 1 of Table S6). This is because
the resulting phenotype distributions across genotypes
differed in shape and their differences were not well
captured by only mean and variance parameters. (The
JLS-Fisher test could, in theory, be extended to include
the skewness parameter or higher moments of such a dis-
tribution. The gain in power for this particular setting,
however, would be associated with power loss for other
approximately normally distributed traits.) In this sce-
nario, when the phenotype deviated from normality, the
LRT method appeared to be most powerful (power ¼
0.996). However, further analysis using permutation esti-
mation of p values showed that power of the LRT under
asymptotic analysis was greatly inflated, whereas the pro-
posed JLS methods were robust (Table S7).
The alternative distribution16 and LRT17 joint testing
methods were proposed for analysis of single SNPs. In
principle, they can be extended to gene-set or pathway
analysis, but multiple issues arise in implementation. The
distribution test statistic depends on the size of the geno-
type groups for each variant, so it is not clear what the
best strategy is to combine the statistics across SNPs with
different MAFs. The LRT method is sensitive to the
normality assumption of the phenotype distribution and
to small group size of the genotype distribution (Tables
S1 and S2).
The proposed multivariate JLS testing method is also
extremely relevant for single-variant association analysis.
In GWAS or Next-Generation Sequencing (NGS) settings
where millions or tens of millions of SNPs are investi-
gated, rapid screening of the whole genome to correctly
prioritize SNPs for further examination demands methods
that are powerful, yet computationally efficient. The pro-
posed JLS testing method is robust and easy-to-imple-
ment, suitable for large-scale whole-genome scans, and
can reveal individual genetic variants with main and/or
interaction effects without the need to explicitly specify
the interacting genetic and/or environmental variables.
Compared with the distribution test and LRT alternatives,
our method combines both simplicity of implementation
and robustness to small size of the rare homozygous geno-
type group.
Our simulation analyses also demonstrated that the
location (regression) and scale (Levene’s) tests, and conse-
quently our JLS-Fisher and JLS-minP tests, are robust to
poorly captured genotype data. These findings agree with
the results of Kutalik et al.41 where minimal to no bias in136 The American Journal of Human Genetics 97, 125–138, July 2, 20false positive rates and type 1 error was found for loca-
tion-only association testing of quantitative phenotypes
with uncertain genotypes, specifically when imputed
genotype probabilities were converted to most-likely geno-
type categories and analyzed without explicitly accounting
for the uncertainty.
Violations of the normal data assumption can affect the
type 1 error level of the proposed JLS test method as it
does the LRT approach (increased type 1 error rate is
more severe with LRT). This is largely due to the assump-
tion of independence between the individual location-
only and scale-only tests, which is required for the c24
approximation of the JLS-Fisher statistic. To circumvent
this issue, investigators might choose to rely on a permu-
tation distribution when estimating p values. However,
this aspect can impose computation challenges at the
genome-wide level. An alternative approach is to model
the dependency between the individual location and scale
test statistics and obtain an adjusted distribution for the
JLS statistic. These adjusted distributions have been
explored elsewhere under complete specification of the
dependency structure between the test statistics being
combined.42–44 However, it remains to be explored how
to model the dependency between the individual location
and scale association test statistics at different loci across
the genome.
In consideration of the choices available for the individ-
ual location and scale tests and the methods of combining
information from these individual components for each
variant, we recognize that there is no single, most powerful
method for all circumstances.20,22 We showed that for nor-
mally distributed traits, the JLS-Fisher test statistic WF fol-
lows a c24 distribution under the null hypothesis, as long as
the location test statistic is a function of the complete suf-
ficient statistic (e.g., linear regression t-statistic, ANOVA
F-statistic) and the distribution of the scale test statistic
does not depend on the model parameters (e.g., Levene’s
test or the F-test for equality of variances). In practice,
when the normality assumption is violated or other JLS
tests are preferred, permutation-based p value evaluation
can be used with increased computational cost.
The proposed framework can be easily extended for
meta-analysis, where the sample- or study-specific associa-
tion test statistics or p values to be combined across sam-
ples are obtained from the JLS testing application instead
of the typical location-only testing method. The sample-
specific choices of the individual location and scale tests
need not be identical across different studies, as long as
p values of the JLS tests are valid within each study. How-
ever, choice of optimal weighting factors assigned to indi-
vidual samples requires further investigation. Analyzing
imputed SNPs (explicitly incorporating the genotype prob-
abilities) or correlated subjects (i.e., pedigree family data)
using the proposed JLS framework would require develop-
ment of appropriate scale-only testing methods; location-
only methods for these more complex settings are already
available.39,45–4915
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